5-MAPBT

5-MAPBT
Clinical data
Other namesMY400[1]
ATC code
  • none
Identifiers
IUPAC name
  • 1-(1-Benzothiophen-5-yl)-N-methylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC12H15NS
Molar mass205.32 g·mol−1
3D model (JSmol)
SMILES
  • CC(CC1=CC2=C(C=C1)SC=C2)NC
InChI
  • InChI=1S/C12H15NS/c1-9(13-2)7-10-3-4-12-11(8-10)5-6-14-12/h3-6,8-9,13H,7H2,1-2H3
  • Key:SKSFWFUEBKJIAJ-UHFFFAOYSA-N

5-MAPBT (5-methylaminopropylbenzothiophene) is an empathogenic drug of the benzothiophene group. It is closely related to 5-MAPB but with the oxygen atom replaced by sulfur, changing the core ring structure to benzothiophene rather than benzofuran.[2]

It has been patented by Tactogen as an entactogen for potential use as a medicine.[2]

See also

References

  1. ↑ Mydecine (5 January 2024). "Novel short-acting psychoactive compounds of the mdma class". Google Patents. Retrieved 23 October 2024.
  2. 1 2 WO 2022/010937, Baggott M, "Advantageous benzothiophene compositions for mental disorders or enhancement.", published 13 January 2022, assigned to Tactogen Inc.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.